Sanofi’s new drug, Dabital, has been approved for children in China

2022-06-18 0 By

Sanofi (Nasdaq: SANofi) today announced that the State Medical Products Administration of China (SDA) approved dabidine (dupriuzumab injection) for the treatment of moderate to severe atopic dermatitis in children and adults aged 6 years and older who are poorly controlled or whose use of topical drugs is not recommended.Dabital is an innovative first-line treatment for atopic dermatitis.”The approval of dabital for children is another important milestone in the treatment of atopic dermatitis in China,” said Xie Lijuan, General Manager of Sanofi Global Business Unit in China.Children are at a critical stage of growth and development, and their healthy growth is related to the future of their families and the country. Safety is the most important consideration for these patients.”2022 marks the 40th anniversary of Sanofi’s presence in China. Looking ahead, we will continue to work closely with all parties to transform the practice of medicine and pursue scientific miracles for the benefit of the Chinese people.”Dabital has been approved in more than 60 countries and regions worldwide and is the first targeted biologic agent for the treatment of moderate to severe atopic dermatitis.In May 2019, Dabital was included in the list of the second batch of clinically urgent overseas new Drugs of The Drug Evaluation Center (CDE) of the State Medical Products Administration to accelerate the marketing approval process.In June 2020, dabital was approved for the treatment of moderate to severe atopic dermatitis in adults, two years ahead of schedule, and is now included in the 2020 National Medical Insurance Directory.In June 2021, Dabital received priority approval in China for indications for children aged 6 and above to 12 years old.In September 2021, dabital was approved in China for the treatment of moderate to severe atopic dermatitis in adolescents and adults aged 12 years and older with poorly controlled or not recommended external medication.(Economic Daily reporter Yuan Yong) statement: this article copyright belongs to the original author, if there is a source error or infringement of your legitimate rights and interests, you can contact us through the mailbox, we will promptly deal with.Email address: jpbl@jp.jiupainews.com